HIV/AIDS Clinical Trials Networks Revised
Posted on: Thursday, 29 June 2006, 18:00 CDT
The U.S. National Institute of Allergy and Infectious Diseases announced Thursday the new structure of its HIV/AIDS clinical trials networks.
The NIAID, part of the National Institutes of Health, said the networks will search for safe and effective treatments and prevention strategies, including HIV vaccines.
The new network structure expands our clinical research capacity and strengthens our ability to take advantage of emerging scientific opportunities, said NIAID Director Dr. Anthony Fauci. By creating a more integrated, collaborative and flexible structure, we will be better equipped to meet evolving global AIDS research priorities.
The principal investigators and institutions leading the newly restructured HIV/AIDS networks are:
-- AIDS Clinical Trials Group -- Dr. Constance Benson of the University of California-San Diego.
-- HIV Prevention Trials Network -- Dr. Sten Vermund of Vanderbilt University.
-- HIV Vaccine Trials Network -- Dr. Lawrence Corey of The Fred Hutchinson Cancer Research Center.
-- International Maternal Pediatric Adolescent AIDS Clinical Trials -- Dr. Jay Brooks Jackson of the Johns Hopkins University School of Medicine.
-- International Network for Strategic Initiatives in Global HIV Trials -- James Neaton of the University of Minnesota.
-- Microbicide Trials Network -- Sharon Hillier of the Magee-Women's Research Institute.
Source: United Press International
Related Articles
- Kendle's TrialEAS(TM) Electronic Adjudication System Named 'Best Technological Development in Clinical Trials - Software Solution' in GCPj Clinical Research Excellence Awards
- Pelosi Remarks at amfAR Conference on Future Directions in Fight Against HIV/AIDS
- HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
- Phase 1 Clinical Trials For HIV/AIDS Vaccine Underway
- BET Networks' Award-Winning Rap-It-Up HIV/AIDS Campaign Partners With City of Baton Rouge to Host a Women's Health Conference On Tuesday, August 21
- Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer In HIV/AIDS Diarrhea Assessment
- GeoVax Launches Clinical Human Trials for Its HIV/AIDS Vaccine Developed at GeoVax Inc., Emory University, NIH and the CDC
- New HIV/AIDS Cases on the Rise in Women and Girls
- The Uganda Virus Research Institute (UVRI), in Collaboration With the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics, Launches HIV/AIDS Vaccine Trial in Entebbe, Uganda
User Comments (0)

RSS Feeds